Stockscreener 앱 받기
8.55
3.76%
0.31
전일 마감가:
$8.24
열려 있는:
$8.15
하루 거래량:
8.20M
Relative Volume:
1.36
시가총액:
$2.61B
수익:
$32.77M
순이익/손실:
$-440.22M
주가수익비율:
-3.817
EPS:
-2.24
순현금흐름:
$-400.48M
1주 성능:
+4.52%
1개월 성능:
-14.16%
6개월 성능:
-17.23%
1년 성능:
+58.48%
1일 변동 폭
$8.08
$8.715
1주일 범위
$7.98
$8.715
52주 변동 폭
$5.41
$18.33
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
명칭
Iovance Biotherapeutics Inc
전화
(650) 260-7120
주소
825 INDUSTRIAL ROAD, SAN CARLOS
IOVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| IOVA | 8.55 | 2.61B | 32.77M | -440.22M | -400.48M | -2.24 |
| VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-09-18 | 재확인 | Barclays | Overweight |
| 2023-05-30 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-31 | 개시 | Guggenheim | Neutral |
| 2022-08-18 | 재개 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2021-06-10 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-05-03 | 개시 | Truist | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2021-03-08 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | 개시 | Mizuho | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-02-26 | 재확인 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-04-29 | 개시 | Piper Jaffray | Overweight |
| 2019-02-28 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-07 | 개시 | Robert W. Baird | Outperform |
| 2018-12-31 | 재개 | B. Riley FBR | Buy |
| 2018-07-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-04-10 | 업그레이드 | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | 재확인 | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-01 | 재확인 | B. Riley FBR, Inc. | Buy |
모두보기
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
10 Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
2 Innovative Stocks That Could Deliver Outsize Returns - Yahoo Finance
Iovance Biotherapeutics Inc. (IOVA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
Iovance Biotherapeutics (STU:2LB) Shares Outstanding (EOP) : 304.62 Mil (As of Sep. 2024) - GuruFocus.com
Long Term Trading Analysis for (IOVA) - Stock Traders Daily
Perceptive Advisors LLC's Strategic Acquisition in Iovance Bioth - GuruFocus.com
Iovance Biotherapeutics director Maynard sells $503k in stock - Investing.com
IOVA (Iovance Biotherapeutics) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Iovance Biotherapeutics' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Australia
Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Principal Financial Group Inc. - MarketBeat
Iovance Biotherapeutics Q3: A Beat, But A SelloffNow A Buy Opportunity - Seeking Alpha
HC Wainwright Has Positive Outlook for IOVA FY2027 Earnings - MarketBeat
Earnings call: Iovance reported a third-quarter product revenue of $58.6 million - Investing.com India
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance UK
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2024 Earnings Call Transcript - Insider Monkey
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line - MSN
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap DownTime to Sell? - MarketBeat
Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlig - GuruFocus.com
Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
Q3 Earnings Estimate for IOVA Issued By HC Wainwright - MarketBeat
Iovance Biotherapeutics’ Strong Q3 2024 Performance - TipRanks
Iovance falls 12% despite Q3 beats; reaffirms 2024 revenue guidance - MSN
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Iovance Biotherapeutics: Q3 Earnings Snapshot - San Francisco Chronicle
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 - GlobeNewswire
Iovance Biotherapeutics earnings beat by $0.02, revenue topped estimates - Investing.com UK
Iovance Q3 Revenue Surges to $58.6M as Amtagvi Launch Gains Momentum | IOVA Stock News - StockTitan
A Peek at Iovance Biotherapeutics's Future Earnings - Benzinga
HC Wainwright Reaffirms Buy Rating for Iovance Biotherapeutics (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics Options Trading: A Deep Dive into Market Sentiment - Benzinga
High Growth Tech Stocks to Watch in November 2024 - Simply Wall St
Iovance Biotherapeutics (IOVA) Set to Announce Earnings on Thursday - MarketBeat
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024 - The Manila Times
Iovance Biotherapeutics to Host Third Quarter and - GlobeNewswire
(IOVA) Trading Report - Stock Traders Daily
Is Iovance Biotherapeutics Stock a Buy Now? - MSN
Why Iovance Biotherapeutics (IOVA) Stock is Moving Today - GuruFocus.com
Why Iovance Biotherapeutics Stock Triumphed on Thursday - MSN
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 6.5%Time to Buy? - MarketBeat
Smart Money Is Betting Big In IOVA Options - Benzinga
Iovance Biotherapeutics (NASDAQ:IOVA) Now Covered by Analysts at UBS Group - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Investors Purchase High Volume of Iovance Biotherapeutics Call Options (NASDAQ:IOVA) - MarketBeat
State Street Corp's Strategic Acquisition in Iovance Biotherapeutics Inc - Yahoo Finance
First Week of October 18th Options Trading For Iovance Biotherapeutics - Nasdaq
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 5.7%Should You Buy? - MarketBeat
Is Iovance Biotherapeutics Inc. (IOVA) the Most Promising Stock to Buy According to Wall Street Analysts? - Insider Monkey
Iovance Biotherapeutics Inc (IOVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):